Moreover, in a transfer IBD model, the anti-CX3CL1 monoclonal antibodies effectively mitigated the reduction in body weight, alleviated diarrhea, and reduced colon thickness. This evidence concerns the gene CX3CL1 and inflammatory bowel disease.